Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection

Saved in:
Bibliographic Details
Published in:Leukemia 2020-11, Vol.34 (11), p.3055-3059
Main Authors: Yang, Chunmei, Xie, Mixue, Zhang, Kaifeng, Liu, Hui, Liang, Aibin, Young, Ken H., Qian, Wenbin
Format: Article
Language:English
Subjects:
13/31
631/67/1990/291/1621/1915
692/499
Antigens, CD19 - immunology
Cancer Research
Care and treatment
CD19 antigen
Cell receptors
Cell therapy
Cellular therapy
Chronic infection
Critical Care Medicine
Development and progression
Genetic aspects
Health aspects
Hematology
Hepatitis B virus
Hepatitis B virus - physiology
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - diagnosis
Hepatitis B, Chronic - virology
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Intensive
Internal Medicine
Letter
Lymphocytes
Lymphocytes T
Lymphoma, Large B-Cell, Diffuse - complications
Lymphoma, Large B-Cell, Diffuse - therapy
Lymphomas
Medicine
Medicine & Public Health
Methods
Oncology
Patient outcomes
T cells
Viral Load
Virus Activation - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-020-0913-y